Targeted and non‐targeted metabolite identification of MAM‐2201 in human, mouse, and rat hepatocytes
Authors:
- 2 April 2018
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 10 (8) , 1328-1335
Abstract
MAM‐2201 is a fluorinated naphthoylindole synthetic cannabinoid with potent psychoactive properties that has been detected as an active ingredient in herbal incense blends. To gain a greater understanding of MAM‐2201 metabolism and to compare its metabolic fate in humans with those in animals, the metabolism of MAM‐2201 in human, mouse, and rat hepatocytes was investigated using liquid chromatography–high‐resolution mass spectrometry combined with targeted and non‐targeted metabolite profiling approaches. Nineteen phase I metabolites (M1–M19) reported previously in human liver microsomes and 13 novel metabolites were identified in human, mouse, and rat hepatocytes: 1 phase I metabolite (M20) and 12 phase II metabolites including 6 glucuronides (G1–G6), 1 sulfate (S1), and 5 glutathione (GSH) conjugates (GS1–GS5) of MAM‐2201 metabolites. G3 was human‐specific, but M20, G1, G2, and 5 GSH conjugates were rat‐specific, indicating species‐related differences in MAM‐2201 metabolism. The findings in the present study can be useful for the experimental design and assessment of metabolism‐mediated toxic risk of MAM‐2201.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2015M3A9E1028325, NRF-2017R1A4A1015036, NRF-2017M3A9F5028608)
This publication has 19 references indexed in Scilit:
- High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMSInternational journal of legal medicine, 2015
- Trends of novel psychoactive substances (NPSs) and their fatal casesForensic Toxicology, 2015
- Novel halogenated derivates of JWH-018: Behavioral and binding studies in miceNeuropharmacology, 2015
- MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptorsNeuropharmacology, 2015
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptorsToxicology and Applied Pharmacology, 2013
- Acute intoxication by synthetic cannabinoids – Four case reportsDrug Testing and Analysis, 2013
- A fatal case of MAM-2201 poisoningForensic Toxicology, 2013
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activityBiochemical Pharmacology, 2012
- LC-MS-Based Metabolomics in Drug MetabolismDrug Metabolism Reviews, 2007
- Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in ratsPsychopharmacology, 2001